Table 3.

Clinical characteristics of control patients

Patient Number	Birth Weight, g	Sex	Gestational Age, wk	CAD, days	Duration FiO2 >0.50, days	Mechanical Ventilation, days	Cause of Death/autopsy Diagnosis and Medication/material Available
Control group age matched to the BPD group (Table 2) for CAD
7	1,625	M	33	3	0	0	Congenital heart malformation. Drugs: atropine, prostaglandin A1 (r)
8	2,350	M	35	<1	0	<1 h	Perinatal asphyxia. Drugs: atropine, adrenaline (h+r)
9	1,740	F	34	<1	0	0	Intrauterine death (ventriculomegaly) (r)
10	1,800	M	32	5	0	5	Meningoencephalitis (h+r)
11	1,190	M	31	<1	0	0	Placental abruption (h+r)
Median	1,740		33
Means ± SE	1,741 ± 186		33 ± 0.7
Control group matched to the BPD group (Table 2) for birth weight and GAB
12	954	M	26	<1	0	0	Intracranial hemorrhage (h+r)
13	914	M	27	<1	0	0	DiGeorge syndrome (22q11.2 deletion); intrauterine infection (h+r)
14	826	M	29	<1	0	0	Hydrocephalus, Arnold Chiari malformation (h+r)
15	852	M	27	<1	0	0	Hypoxic-ischemic encephalopathy (r)
16	995	M	27	<1	0	0	Placental abruption (h+r)
17	758	M	26	<1	0	0	Intrauterine infection (h+r)
Median	914		27
Means ± SE	929 ± 55		27 ± 0.4

h, histological sections; r, RNA.